SUMMARY - US Healthcare Influence
In the quiet corridors of a specialized oncology unit in Vancouver, Dr. Elena Rossi reviews the chart of a patient diagnosed with a rare form of leukemia. The standard treatment protocol in Canada involves a drug that is available but subject to lengthy approval and reimbursement processes through the provincial drug plan. Across the border in Seattle, a colleague informs her that a newer, more potent inhibitor has just received FDA approval and is already being administered in clinical trials. Dr.